Sangamo Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Sangamo Therapeutics

25/04/2023 03:02

* Sangamo Therapeutics Inc  SGMO.OQ   SGMO.O  is expected
to show
a fall in quarterly revenue when it reports  results on April
26. 
    * The Brisbane California California-based  company is
expected to
report  a 14.8% decrease in revenue to $24.065 million from
$28.23 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Sangamo
Therapeutics Inc
is for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $11​, above​ its last closing price
of $1.65. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.35       -0.36      -0.32     Beat    11.1
 Sep. 30 2022  -0.34       -0.36      -0.34     Beat    4.3
 Jun. 30 2022  -0.33       -0.35      -0.29     Beat    17.8​
 Mar. 31 2022  -0.31       -0.31      -0.30     Beat    3.5
 ​​Dec.        -0.35       -0.35      -0.26     Beat    24.7
 31 2021                                                
 Sep. 30 2021  -0.34       -0.34      -0.33     Beat    2.1​
 Jun. 30 2021  -0.33       -0.31      -0.33     Missed  -5.5
 Mar. 31 2021  -0.30       -0.29      -0.32     Missed  -9
 This summary was machine generated April 25 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated